These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23922054)

  • 1. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
    Xin Y; Jin D; Eppler S; Damico-Beyer LA; Joshi A; Davis JD; Kaur S; Nijem I; Bothos J; Peterson A; Patel P; Bai S
    J Clin Pharmacol; 2013 Nov; 53(11):1103-11. PubMed ID: 23922054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.
    Han K; Chanu P; Jonsson F; Winter H; Bruno R; Jin J; Stroh M
    AAPS J; 2017 Mar; 19(2):527-533. PubMed ID: 28028730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.
    Nishio M; Horiike A; Nokihara H; Horinouchi H; Nakamichi S; Wakui H; Ohyanagi F; Kudo K; Yanagitani N; Takahashi S; Kuboki Y; Yamamoto N; Yamada Y; Abe M; Tahata T; Tamura T
    Invest New Drugs; 2015 Jun; 33(3):632-40. PubMed ID: 25777467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.
    Xiang H; Bender BC; Reyes AE; Merchant M; Jumbe NL; Romero M; Davancaze T; Nijem I; Mai E; Young J; Peterson A; Damico-Beyer LA
    Clin Cancer Res; 2013 Sep; 19(18):5068-78. PubMed ID: 23894056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
    Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
    J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
    Salgia R; Patel P; Bothos J; Yu W; Eppler S; Hegde P; Bai S; Kaur S; Nijem I; Catenacci DV; Peterson A; Ratain MJ; Polite B; Mehnert JM; Moss RA
    Clin Cancer Res; 2014 Mar; 20(6):1666-75. PubMed ID: 24493831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.
    Spigel DR; Edelman MJ; Mok T; O'Byrne K; Paz-Ares L; Yu W; Rittweger K; Thurm H;
    Clin Lung Cancer; 2012 Nov; 13(6):500-4. PubMed ID: 23063071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
    Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
    Lu JF; Eppler SM; Wolf J; Hamilton M; Rakhit A; Bruno R; Lum BL
    Clin Pharmacol Ther; 2006 Aug; 80(2):136-45. PubMed ID: 16890575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
    Penuel E; Li C; Parab V; Burton L; Cowan KJ; Merchant M; Yauch RL; Patel P; Peterson A; Hampton GM; Lackner MR; Hegde PS
    Mol Cancer Ther; 2013 Jun; 12(6):1122-30. PubMed ID: 23536720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
    Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
    Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
    Bendell JC; Ervin TJ; Gallinson D; Singh J; Wallace JA; Saleh MN; Vallone M; Phan SC; Hack SP
    Clin Colorectal Cancer; 2013 Sep; 12(3):218-22. PubMed ID: 23810377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.
    Noh YH; Lim HS; Jung JA; Song TH; Bae KS
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):97-109. PubMed ID: 25377158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
    Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
    Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.